The Cancer Drug Development Forum (CDDF) Annual conference is a unique forum that convenes every year and gathers the leaders in the world of innovative cancer therapy development, including medical researchers, pharmaceutical industry representatives, regulatory authority representatives, and patient advocacy groups. The 12th edition took place from 7 to 9 February 2022.
Due to lasting Covid-19 measures, the CDDF Annual Conference was switched to fully virtual format.
This multi-stakeholder, interactive meeting offers plenary lectures with moderated discussions, including case studies as well as networking opportunities. The programme focus on the latest and future challenges of Innovative oncology drug development with a special emphasis on integration of regulatory assessment and the assessment of reimbursement of novel agents, enhancing the future of (de-central) clinical trials, lessons learned from acceleration in pediatric oncology drug development programs, and global regulatory collaborations in oncology drug development assessment.
- Understanding current differences in the European regulatory approval- and HTA approaches and discussing potentials for harmonization and alignment.
- Forward facing discussion on de-central cancer clinical trial performance, and on use of digital tools for this purpose.
- Forward facing discussion on options to accelerate drug development programs
- Understanding the current status of global regulatory collaboration, and open discussion on options for further extension.
The target was a multidisciplinary audience of representatives from academia, EU and US regulatory bodies (EMA, FDA, and national agencies), the pharmaceutical industry, HTAs, and patient advocates.